The efficacy of delgocitinib ointment for rosacea and rosacea-like dermatitis
- Conditions
- rosacea, rosacea-like dermatitisrosasea, rosacea-like dermatitis, erythema, telangiectasia
- Registration Number
- JPRN-jRCTs061210078
- Lead Sponsor
- Kajita Ai
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
1)Patients aged 20 years or over at the time of agreement
2)Patient who have agreed by their own decision, with the written consent form, following the appropriate procedure of informed- consent.
3)Patient diagnosed as rosacea or rosacea-like dermatitis.
4)Patient that with refractory rosacea or rosacea-like dermatitis despite the standard treatments for 12 weeks or more
5)Patient without a history of delgocitinib ointment therapy
1)Patient who have previously been treated with delgocitinib ointment.
2)Patients with any of the following disease to be differentiated: seborrheic dermatitis, atopic dermatitis (rosacea-like dermatitis arising in a patient with atopic dermatitis is not excluded), contact dermatitis, acne vulgaris, dermatomyositis, lupus erythematosus, drug eruption, lupus miliaris disseminatus faciei, eosinophilic pustular folliculitis, dermatomycosis and photo-allergy.
3)Miscellaneous: Patient who are considered ineligible for enrolling the study by a principal investigator or co-investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Score of clinical manifestations eight items (hot flashes, erythema, papules pustule, telangiectasia, itch, situation, drying, edema)
- Secondary Outcome Measures
Name Time Method 1)presence or absence of adverse events 2) EASI score 3) NRS 4)IGA 5) Skindex-16 6)presence or absence of demodex